Takeda holder plans sale of 4,319 ADSs
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs). The planned sale covers up to 4,319 ADSs of Takeda, to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE. The securities to be sold were received as Restricted Stock Unit awards that vested on July 1, 2026, with a separate entry showing 13,988 ADSs acquired on that date as compensation.
Key Figures
Key Terms
Restricted Stock Unit Awards financial
compensation financial
Interactive Brokers LLC financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Form 144-style filing indicate for Takeda (TAK)?
How many Takeda (TAK) ADSs are planned for sale and through whom?
What is the approximate market value of the Takeda (TAK) ADSs to be sold?
When were the Takeda (TAK) ADSs being sold originally acquired?
On what date is the Takeda (TAK) ADS sale expected to occur?
What type of security is involved in this Takeda (TAK) planned sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.